These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

128 related articles for article (PubMed ID: 11577785)

  • 1. The therapeutic effect of lipo PGE1 on diabetic neuropathy-changes in endothelin and various angiopathic factors.
    Itoh Y; Yasui T; Kakizawa H; Makino M; Fujiwara K; Kato T; Imamura S; Yamamoto K; Hishida H; Nakai A; Itoh M; Nagasaka A
    Prostaglandins Other Lipid Mediat; 2001 Oct; 66(3):221-34. PubMed ID: 11577785
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The relation between plasma endothelin-1 levels and metabolic control, risk factors, treatment modalities, and diabetic microangiopathy in patients with Type 2 diabetes mellitus.
    Ak G; Buyukberber S; Sevinc A; Turk HM; Ates M; Sari R; Savli H; Cigli A
    J Diabetes Complications; 2001; 15(3):150-7. PubMed ID: 11358684
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Clinical efficacy of different doses of lipo-prostaglandin E1 in the treatment of painful diabetic peripheral neuropathy.
    Hong L; Zhang J; Shen J
    J Diabetes Complications; 2015; 29(8):1283-6. PubMed ID: 26355026
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Prostaglandin E1 in lipid microspheres ameliorates diabetic peripheral neuropathy: clinical usefulness of Semmes-Weinstein monofilaments for evaluating diabetic sensory abnormality.
    Akahori H; Takamura T; Hayakawa T; Ando H; Yamashita H; Kobayashi K
    Diabetes Res Clin Pract; 2004 Jun; 64(3):153-9. PubMed ID: 15126001
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Lipo-PGE1, a new lipid-encapsulated preparation of prostaglandin E1: placebo-and prostaglandin E1-controlled multicenter trials in patients with diabetic neuropathy and leg ulcers.
    Toyota T; Hirata Y; Ikeda Y; Matsuoka K; Sakuma A; Mizushima Y
    Prostaglandins; 1993 Nov; 46(5):453-68. PubMed ID: 8278621
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effects of a single drip infusion of lipo-prostaglandin E1 on vibratory threshold in patients with diabetic neuropathy.
    Tawata M; Nitta K; Kurihara A; Nagasaka T; Iwase E; Gan N; Inoue M; Onaya T
    Prostaglandins; 1995 Jan; 49(1):27-39. PubMed ID: 7792389
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Hemodynamic effects of lipo-PGE1 on peripheral artery in patients with diabetic neuropathy: evaluated by two-dimensional color Doppler echography.
    Okuda Y; Mizutani M; Ogawa M; Sone H; Asano M; Tsurushima Y; Morishima Y; Asakura Y; Suzuki S; Isaka M
    Diabetes Res; 1993; 22(2):87-95. PubMed ID: 8205741
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prostaglandin E1 incorporated in lipid microspheres in the treatment of peripheral vascular diseases and diabetic neuropathy.
    Hoshi K; Mizushima Y; Kiyokawa S; Yanagawa A
    Drugs Exp Clin Res; 1986; 12(8):681-5. PubMed ID: 3757764
    [TBL] [Abstract][Full Text] [Related]  

  • 9. PGE1 improves diabetic peripheral neuropathy in patients with type 2 diabetes.
    Wu JD; Tao S; Jin X; Jiang LL; Shen Y; Luo Y; Zhang P; Lee KO; Ye L; Ma JH
    Prostaglandins Other Lipid Mediat; 2016 Nov; 126():24-28. PubMed ID: 27421690
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Integrated Treatment of Prostaglandin E1 and Angiotensin-Converting Enzyme Inhibitor in Diabetic Kidney Disease Rats: Possible Role of Antiapoptosis in Renal Tubular Epithelial Cells.
    Mou Y; Zhang Y; Guo C; Zhao J; Zhang Z; Zhou X; Dong J; Liao L
    DNA Cell Biol; 2018 Feb; 37(2):133-141. PubMed ID: 29185789
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Relationship between plasma sialic acid concentration and microvascular and macrovascular complications in type 1 diabetes: the EURODIAB Complications Study.
    Crook MA; Pickup JC; Lumb PJ; Giorgino F; Webb DJ; Fuller JH;
    Diabetes Care; 2001 Feb; 24(2):316-22. PubMed ID: 11213885
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Therapeutic effects of prostaglandin E1 in diabetic patients].
    Taveggia G; Selletti L
    Minerva Cardioangiol; 2003 Jun; 51(3):317-22. PubMed ID: 12867884
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Risk factors for the development of micro-vascular complications of type 2 diabetes in a single-centre cohort of patients.
    Teliti M; Cogni G; Sacchi L; Dagliati A; Marini S; Tibollo V; De Cata P; Bellazzi R; Chiovato L
    Diab Vasc Dis Res; 2018 Sep; 15(5):424-432. PubMed ID: 29911415
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Assays of serum laminin and type III procollagen peptide for monitoring the clinical course of diabetic microangiopathy.
    Okazaki R; Matsuoka K; Horiuchi A; Maruyama K; Okazaki I
    Diabetes Res Clin Pract; 1988 Sep; 5(3):163-70. PubMed ID: 3219988
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Catalase/superoxide dismutase (SOD) and catalase/paraoxonase (PON) ratios may implicate poor glycemic control.
    Sözmen EY; Sözmen B; Delen Y; Onat T
    Arch Med Res; 2001; 32(4):283-7. PubMed ID: 11440784
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effect of prostaglandin E1 on the renin-aldosterone system in patients with diabetic nephropathy.
    Okada S; Ichiki K; Tanokuchi S; Ishii K; Hamada H; Ota Z
    J Int Med Res; 1993; 21(3):126-32. PubMed ID: 8299855
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Can glycaemic variability, as calculated from blood glucose self-monitoring, predict the development of complications in type 1 diabetes over a decade?
    Bragd J; Adamson U; Bäcklund LB; Lins PE; Moberg E; Oskarsson P
    Diabetes Metab; 2008 Dec; 34(6 Pt 1):612-6. PubMed ID: 18824382
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Retinopathy, neuropathy and nephropathy in non-insulin-dependent diabetic patients.
    Tai TY; Tseng CH; Sung SM; Huang RF; Chen CZ; Tsai SH
    J Formos Med Assoc; 1991 Oct; 90(10):936-40. PubMed ID: 1685173
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Elevated plasma levels of transforming growth factor-beta 1 in NIDDM.
    Pfeiffer A; Middelberg-Bisping K; Drewes C; Schatz H
    Diabetes Care; 1996 Oct; 19(10):1113-7. PubMed ID: 8886558
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Lipo-prostaglandin E1 improves renal hypoxia evaluated by BOLD-MRI in patients with diabetic kidney disease.
    Li ZC; Cai YZ; Tang ZG; Zuo PL; Liu RB; Liu F
    Clin Imaging; 2018; 50():239-242. PubMed ID: 29689479
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.